Amarantus issues Chinese patent covering use of MANF for the treatment of Parkinson's

 29 Jan 2016

The patent issuance will provide intellectual property protection in China for protein therapy, gene therapy and cell therapy applications of MANF.

Amarantus develops treatments and diagnostics for diseases in the areas of regenerative medicine neurology, and orphan diseases.

Amarantus BioScience Holdings (OTCMKTS:AMBS), a biotechnology company, issued a Chinese patent entitled "Neurodegenerative Disorders" covering the use of MANF for the treatment of Parkinson's disease.

The claims issued extend patent coverage for MANF protein therapy, gene therapy and cell therapy applications into 2029, the San Francisco, California-based company said in a statement on Thursday.

"The Chinese market represents a potential significant market opportunity for Amarantus," CEO Gerald Commissiong said in the statement.

The company said on Friday that it will look to partner the development of MANF with a group in China capable of bringing that technology to market in that region.

This patent adds to Amarantus' international intellectual property portfolio covering compositions of matter, methods of use and formulations for MANF.

Shares fell 8.6% to $0.323 at 12:21 p.m. in New York, reversing an earlier gain

http://www.proactiveinvestors.com/companies/news/121962/amarantus-issues-chinese-patent-covering-use-of-manf-for-the-treatment-of-parkinson-s-121962.html?